• Idorsia announced enrollment of the first patients in its Dari-Dream insomnia study on October 27, 2026.
• The trial evaluates QUVIVIQ (daridorexant) 50 mg in adults and elderly patients to support a US label update covering daytime functioning benefits.
• Previous Phase 3 results showed improvements in daytime alertness, mood and sleepiness with the 50 mg dose.
• These benefits are already reflected in prescribing information in multiple countries, including across Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270200OMX_____CNEWS_EN_GNW1001280018_en) on October 27, 2026, and is solely responsible for the information contained therein.